Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof

Phenylaminopyrimidinamide compounds targeting ULK kinase activity provide a selective and less toxic means to inhibit autophagy in cancer and neurodegenerative diseases, enhancing therapeutic efficacy when combined with other treatments.

JP7593947B2Active Publication Date: 2024-12-03DECIPHERA PHARMACEUTICALS LLC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2021566469
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-10-07
Filing Date
2020-05-08
Publication Date
2024-12-03
Estimated Expiration
2040-05-08

Smart Images

  • Figure 0007593947000001
    Figure 0007593947000001
  • Figure 0007593947000002
    Figure 0007593947000002
  • Figure 0007593947000003
    Figure 0007593947000003
Patent Text Reader

Abstract

Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancer. TIFF2022531801000206.tif73100
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Pyrimidine derivatives, pharmaceutical compositions containing these compounds, uses thereof and methods for their preparation

    JP2005509624A

  • chk-, pdk- and akt-inhibiting pyrimidines, their manufacture and pharmaceutical use

    JP2006508997A

  • Novel ulk1 inhibitors and methods of using them

    JP2017526674A

  • Pyrimidine derivatives capable of inhibiting one or more kinases

    WO2009122180A1